(RCUS) Arcus Biosciences - Ratings and Ratios

Arcus Biosciences Inc (NYSE:RCUS) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies in the United States, with a diverse pipeline targeting various types of cancer, including kidney, lung, gastrointestinal, and pancreatic cancer.

The companys product portfolio includes several promising candidates, such as Casdatifan, a HIF-2a inhibitor for kidney cancer, and Domvanalimab, an anti-TIGIT antibody in Phase 2 and 3 clinical trials for lung and gastrointestinal cancers. Other notable candidates include Quemliclustat, Etrumadenant, Zimberelimab, AB598, and AB801, which are in various stages of clinical development.

Notably, Arcus Biosciences has established strategic collaborations with major pharmaceutical companies, including AstraZeneca, to support the development of its candidates, such as the Phase 3 PACIFIC-8 trial evaluating Domvanalimab and Durvalumab in Stage 3 NSCLC. This collaboration is expected to drive progress in the companys pipeline and potentially lead to future approvals.

Analyzing the , we observe that the stocks last price is $8.62, with a SMA20 of $9.27, indicating a potential downward trend. The SMA50 is $8.70, while the SMA200 is $12.73, suggesting a longer-term downtrend. The ATR is 0.59, corresponding to a 6.80% volatility. Given the current price and volatility, we can expect the stock to fluctuate within a range of $8.03 to $9.21 in the short term.

From a fundamental perspective, Arcus Biosciences has a market capitalization of $978.38M USD, with a negative P/E ratio and a Return on Equity (RoE) of -70.58%. This indicates that the company is currently unprofitable, which is not uncommon for a clinical-stage biopharmaceutical company. However, the companys pipeline and collaborations suggest potential for future growth.

Forecasting the stocks performance using both and , we can expect the stock to experience a short-term correction, potentially reaching the SMA50 of $8.70. However, if the companys pipeline candidates demonstrate positive results, particularly in the ongoing Phase 3 trials, we could see a significant upward revision in the stock price, potentially targeting the 52W High of $18.44. Conversely, failure to meet expectations or negative trial results could lead to a decline towards the 52W Low of $6.87.